Dr. Mingzhi Xu 徐明智
Chief Physician
Endocrinology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diabetes and complications, thyroid, adrenal and pituitary disorders, obesity, gout, electrolyte imbalance, endocrine tumors, growth retardation, and intersex conditions.
Dr. Xu holds a PhD in Internal Medicine and serves as a master’s supervisor at Zhejiang University and Zhejiang Chinese Medical University. The doctor holds an Advanced Endocrine Specialist certificate from the UK NHS Trust. Dr. Xu has published nearly 20 papers and led multiple research projects, including grants from the National Natural Science Foundation of China.
Professional roles
- Standing Committee Member, Diabetes Prevention and Management Professional Committee, China Health Management Association
- Committee Member, Blood Glucose Precision Management Expert Committee, China Health Promotion Foundation
- Chair, Endocrinology and Metabolism Professional Committee, Zhejiang Social Medical Association
- Vice Chair, Health and Wellness Professional Committee, Zhejiang Talent Development Association
Name order: in Chinese the family name comes first (Xu Mingzhi). Papers usually list the name as Mingzhi Xu or Xu M.
Selected publications
9 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Lett, 2026 (senior author): ACSL5 drives pancreatic ductal adenocarcinoma by suppressing mitophagy and enhancing ferroptosis resistance via the JAK1-STAT1-OASL axis. PubMed 42692137
- J Diabetes Investig, 2025 (senior author): Construction of a metabolic-immune model for predicting the risk of diabetic nephropathy and study of gut microbiota. PubMed 40029758
- Clin Case Rep, 2025 (senior author): A Pedigree With LHX4 and SOX3 Gene Variants Resulting in Gonadal Dysplasia. PubMed 39991535
- Hepatobiliary Pancreat Dis Int, 2023 (senior author): Risk factors for posttransplant diabetes in patients with hepatocellular carcinoma. PubMed 36690524
- Front Cell Infect Microbiol, 2023 (senior author): Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease. PubMed 36756620
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion